Administration of intravenous immunoglobulin (IVIg) is a recognized safe and efficient immunomodulation therapy for many autoimmune diseases. Anti-idiotypic antibody binding to pathogenic autoantibodies was proposed as one of the mechanisms attributed to the protective activity of IVIg in autoimmunity. The aim of this study was to fractionate the anti-anticitrullinated protein anti-idiotypic-antibodies (anti-ACPA) from an IVIg preparation and to test it as a treatment for collagen-induced arthritis in mice. IVIg was loaded onto an ACPA column. The eluted fraction was defined as ACPA-specific-IVIg (ACPA-sIVIg). Collagen-induced-arthritis (CIA) was induced in mice. Mice were treated weekly with ACPA-sIVIg, lowdose-IVIg, high-dose-IVIg and phosphate-buffered saline (PBS). Sera-ACPA titres, anti-collagen anitbodies and cytokine levels were analysed by enzymelinked immunosorbent assay (ELISA); antibody-forming-cell activity by enzyme-linked imunospot (ELISPOT) assay; and expansion of regulatory T cell (T reg ) population by fluorescence activated cell sorter (FACS). ACPAsIVIg inhibited ACPA binding to citrullinated-peptides (CCP) in vitro 100 times more efficiently than the IVIg compound. ACPA-sIVIg was significantly more effective than the IVIg-preparation in attenuating the development of collagen-induced arthritis. Splenocytes from CIA mice treated with ACPA-sIVIg reduced the ACPA and anti-collagen-antibody titres, including the number of anti-collagen and ACPA antibody-forming cells. In parallel, splenocytes from ACPA-sIVIg treated mice secreted higher levels of anti-inflammatory cytokines and lower proinflammatory cytokines. The ACPA-sIVIg inhibitory potential was accompanied with expansion of the T reg population. Low-dose IVIg did not affect the humoral and cellular response in the CIA mice in comparison to the PBS-treated mice. Based on our results, IVIg may be considered as a safe compound for treating patients with rheumatoid arthritis by neutralizing pathogenic autoantibodies, reducing proinflammatory cytokines and expanding the T reg population.
Introduction
Rheumatoid arthritis (RA) is an autoimmune rheumatic disease that primarily affects the joints and synovial tissue, resulting in inflammation and destruction. Anti-citrullinated protein antibodies (ACPA) are detected in approximately 90% of RA patients and are involved in the pathogenesis of the disease [1] [2] [3] [4] [5] . During the process of inflammation, arginine amino acid residues are converted enzymatically into citrulline in proteins such as collagen, enolase, vimentin, fibrin and fibrinogen, a process termed citrullination. ACPA are pathogenic autoantibodies that can initiate and enhance arthritis in murine models [1] [2] [3] [4] . The mechanism by which ACPA promotes inflammation was proposed to be related to the ACPA activating complement and diverse cells of the immune system. The cell perturbation was attributed to ACPA binding to the Fc-receptor, F(ab) 2 or to cross-linking between the Fc-receptor and B cell receptor (BCR) by ACPA. This scenario involves the complement system, causing secretion of proinflammatory cytokines such as tumour necrosis factor (TNF)-a, recruitment of inflammatory-related cell subsets and formation of neutrophil extracellular traps (NETs) (NETosis) leading to inflammation of the joints [1] [2] [3] [4] [5] . The involvement of ACPA in the inflammatory process indicates the need for therapies aimed at blocking the activity of pathogenic autoantibodies.
Intravenous immunoglobulin (IVIg) therapy has been shown to be beneficial in various autoimmune diseases [6] [7] [8] . IVIg has a therapeutic effect in RA in human and animal models such as collagen-induced arthritis (CIA) [9] [10] [11] [12] . IVIg immunomodulate the humoral and cellular responses of the immune network through the Fab and Fc portions of the immunoglobulins [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . Among the diverse pathways of IVIg activities in autoimmunity, antiidiotypic activity has gained a great deal of attention [13, 14, 16] . Previously, we and others have shown the immunomodulating effects of specific anti-idiotypic IVIg in animal models of autoimmune diseases such as lupus, anti-phospholipid syndrome, myasthenia gravis, vasculitis and pemphigus vulgaris [17] [18] [19] [20] [21] . In the current study, we examined the efficacy of anti-ACPA-specific IVIg (anti-Id) in the treatment of mice with CIA.
Methods
Fractionation of ACPA-specific IVIg (ACPA-sIVIg)
IVIg was supplied by Laboratoire Franc¸ais des Biotechnologies, LFB-Tegeline, France. The high-dose concentration of IVIg used in the study was 3 mg/ml; the low-dose IVIg concentration was 30 lg/ml.
Stage I
For purification of ACPA, total IgG was affinity purified on a Protein-G column (GE Healthcare Bio-Sciences AB, Uppsala, Sweden). Four ml of patient serum diluted five times with phosphate-buffered saline (PBS) was allowed to pass through the column for 4 h at room temperature. The procedure was repeated for 12 patients. The column was then washed with PBS and bound antibodies were eluted with 0Á2 M glycin-HCl pH 2Á2, neutralized to pH 7 and dialysed against PBS.
ACPA from the total IgG was purified on a citrullinated peptide column constructed using a HiTrap column (GE Healthcare). The citrullinated peptides used in the study comprised the following [22, 23] :
HiTrap TM N-hydroxysuccinimide (NHS)-activated-Sepharose TM High Performance (GE Healthcare). The citrullinated peptides were dissolved in coupling buffer (0Á2 M NaHCO 3 , 0Á5 M NaCl, pH 8Á3), 5 mg/10 ml. The isopropanol was washed out with 3 3 2 ml ice-cold 1 mM HCl. Two ml of coupling buffer was added, followed by the peptides solution into the column using a pump at for 4 h at room temperature. The non-bound peptides were washed and deactivated by 0Á5 M ethanolamine 0Á5 M NaCl, pH 8Á3 buffer followed by 0Á1 M acetate, 0Á5 M NaCl, pH 4.
The pH was adjusted with 0Á05 M Na 2 HPO 4 , pH 7. Total fractionated IgG was loaded 2 mg/ml in PBS onto the peptides column. Following extensive washing, the bound ACPA was eluted with 0Á2 M glycin-HCl, pH 2Á5, neutralized immediately to pH 7 and dialysed with PBS.
Stage II
For the construction of the ACPA column, a mix of affinity-purified ACPA antibodies from 12 patients with RA were dialysed against coupling buffer (0Á1 M NaHCO 3 , pH 8Á3, containing 0Á5 M NaCl) overnight at 48C and bound covalently to CN.Br-activated Sepharose 4B (GE Healthcare), according to the manufacturer's instructions. The remaining active NH groups were blocked by incubation with 0Á2 M glycine, pH 8Á0, overnight at 48C. Three washing cycles with coupling buffer, followed by 0Á1 M acetate buffer, pH 4Á0, were used to remove the excess of unbound ACPA. The washed column was equilibrated in sterile Tris-HCl buffer pH 7Á4.
Stage III
For fractionation of IVIG anti-ACPA idiotypic antibodiessIVIG, 500 mg of the commercial IVIG preparation (Omrix, Ness-Ziona, Israel) were dialysed against loading buffer (0Á05 M Tris containing 0Á5 M NaCl, pH 8Á0), diluted in 50 ml of loading buffer, filtered through the 0Á45 lm filter (Minisart, Sartorius AG, G€ ottingen, Germany) and passed through the ACPA column for 16 h at 48C. Unbound material was washed out and the bound antibodies were eluted with 0Á2 M glycine-HCl, pH 2Á2, and neutralized immediately to pH 7.
Mice
Male DBA/1J mice, 6-7 weeks old, were purchased from Harlan Laboratories (Venray, the Netherlands). The mice were kept in individually ventilated cages. All experiments were approved and executed according to the Ethical Committee of the Israeli Ministry of Health, protocol number 787/12.
Induction of arthritis and treatment
Experimental arthritis was induced in male DBA/1J 6-7-week-old mice with bovine type II collagen (CII), which is a prototype model of RA and shares many clinical and histopathological similarities to human RA [12, 24] 
Histological analysis of the joints
Joints from the mice were then embedded in paraffin. The pathology of the joints was identified by histological staining [haematoxylin and eosin (H&E)]. The evaluation was performed by a pathologist.
Screening for autoantibodies by enzyme-linked immunosorbent assay (ELISA)
The determination of circulating mouse ACPA and anticollagen antibodies was performed as follows: human ACPA were detected using collagen-coated cell culture plates (CCP) (Quanta Lite CCP3 IgG ELISA; Inova Diagnostics, Inc., San Diego, CA, USA). Mouse autoantibodies were studied in sera from the different groups of mice. ELISA plates were coated with collagen-II or peptide-mix 10 lg/ml PBS overnight at 48C. Following blocking with 3% bovine serum albumin (BSA), sera were applied at a 1 : 200 dilution for 2 h. The binding was probed by goat antimouse-IgG-alkaline-phosphatase, diluted 1 : 5000 with the appropriate substrate. Data were read by ELISA reader at 405 nm optical density (OD).
Antibody-forming cell activity
In order to clarify whether the lower sera titres of autoantibodies in the ACPA-sIVIg-treated group of mice resulted from fewer B cell-producing antibodies or the decreased ability of B cells to secrete antibodies, we affinity-purified B cells by negative selection using magnetic microbeads (MACS; Miltenyi Biotec, Bergisch Gladbach, Germany) and performed the antibodyproducing cells assay in vitro using the enzyme-linked immunospot (ELISPOT) blue colour module ELISPOT assay (R&D Systems, Minneapolis, MN, USA). The assay was performed using a 96-well polyvinylidene difluoride (PVDF)-backed microplate, according to the manufacturer's protocol. Briefly, 30 mg/ml of citrullinated peptide mix or collagen type II in 100 ml dilution buffer was applied per well to the ELISPOT plate and incubated overnight at 48C. Following washings and blocking with RPMI-1640 supplemented with 10% fetal calf serum (FCS) for 2 h, affinity-purified B cells were seeded at 10 5 cells/well and incubated for 24 h at 378C in 5% CO 2 . Following washing of the cells, the spots of the secreted antibodies were probed with a second antibody goat-anti-mouse IgG conjugated to horseradish peroxidase (HRP) and a specific substrate. The spots were counted.
Cytokine secretion
Splenocytes from the different groups of mice were cultured 5 3 10 6 cells/well in 12-well plates coated with anti-CD3 1 lg/ml in an enriched medium (RPMI-1640 supplemented with 10% FCS, 1% penicillin/streptomycin, 2% glutamic acid and 10 25 M mercaptoethanol) at 378C and 5% CO 2 .
The splenocytes were incubated in the presence of L-IVIg 30 lg/ml, ACPA-sIVIg 30 lg/ml and H-IVIg 3 mg/ml. After 48 and 72 h, the supernatants were harvested for detection of TNF-a, interleukin (IL)-1b and IL-10. The cytokine levels were determined using the sandwich DuoSet ELISA kit (R&D systems), performed according to the manufacturer's instructions. For detection of transforming growth factor (TGF)-b, supernatants were added after activation of a latent TGF-b to immunoreactive TGF-b1. A biotinylated anti-human TGF-b1 antibody was added thereafter, and the assay was developed according to the manufacturer's instructions for the TGF-b kit (R&D Systems). T cell population from different groups of mice was analysed by fluorescence activated cell sorter (FACS). Fluorescein isothiocyanate (FITC) conjugated to anti-mouse-CD4, allophycocyanin (APC) conjugated to anti-mouse CD25 and phycoerythrn (PE) conjugated to anti-mouse/rat FoxP3 were used for the analyses (all from eBioscience, San Diego, CA, USA). After red blood cell lysis, splenocytes were incubated with anti-CD4 anti-CD25 monoclonal antibodies (mAbs) for 1Á5 h at room temperature. Following washing with PBS, the cells were fixed and permeabilized with Fix/ Perm buffer and permeabilization buffer (R&D Systems) overnight at 48C. The next day, anti-FoxP3 was added for 1Á5 h of incubation, washed and analysed by FACS. To visualize CD4 
Flow cytometry analyses

Results
Inhibition of ACPA binding to CCP by anti-idiotypic ACPA-sIVIg
In the first stage, we clarified whether the LFB-IVIg compound encompassed a subfraction of anti-idiotypic antibodies to ACPA. As illustrated in Fig. 1a , biotin-labelled IVIg at a concentration of 3 mg/ml showed significant ACPA binding to CCP, compared to the control IgG (P < 0.002). Whereas IVIg fractionated on an ACPA column, ACPA specific-IVIg (ACPA-sIVIg) bound ACPA at a concentration of 30 mg/ml (P < 0Á002), 100 times stronger than the entire IVIg compound (Fig. 1b) . IVIg and ACPA-sIVIg binding behaved in a dose-dependent manner, as illustrated in Fig. 1a,b . Inhibition experiments were conducted to confirm the stronger activity of ACPA-sIVIg. We studied the ability of ACPA-sIVIg to inhibit ACPA binding to CCP in compared to the entire IVIg compound. Data presented in Fig. 1c show that ACPA-sIVIg inhibited ACPA binding by 90% at a concentration of 30 mg/ml. IVIg at the same concentration inhibited the binding by only 4% (P < 0Á001). High-dose IVIg (3 mg/ml) inhibited ACPA binding to CCP by 75% compared to the control IgG (P < 0Á002). No significant difference was observed between sIVIg and IVIg in inhibiting the ACPA-CCP binding capacity (P > 0Á05). These data indicate the advantage of sIVIG on the IVIg compound.
ACPA-sIVIg attenuated the development of CIA in mice
The clinical arthritis score was significantly lower in ACPAsIVIg treated mice compared with groups treated with low-dose IVIg or PBS (P < 0Á001) at day 38, as illustrated in Fig. 2a . ACPA-sIVIg treatment lowered the clinical score significantly more than H-IVIg at day 38 (P < 0Á03). The histological analysis of the inflammation in the four joints is described in Fig. 2b . Severe inflammation is seen in the joints of PBS-treated mice, as well as in the group of L-IVIg injected mice. Treatment with ACPA-sIVIg or H-IVIg prevented the development of substantial inflammation.
Suppression of the humoral response: lower sera titres of ACPA and anti-CII antibodies and the number of antibody-forming cells in the CIA mice treated with ACPA-sIVIg or H-IVIg Circulating anti-type-II-collagen-(CII) antibody and anti-CCP titres were evaluated in the sera from CIA mice treated with ACPA-sIVIg, L-IVIg or H-IVIg and PBS. The titres of both mouse anti-collagen type II antibodies and ACPA were significantly lower in CIA mice treated with ACPA-sIVIg or high-dose IVIg compared to CIA mice that received low-dose IVIg or PBS (P < 0Á002, P < 0Á001, respectively) at day 38 (Fig. 3) .
We evaluated the activity of the antibody-forming cells (AFC) of the B cells isolated on magnetic beads from splenocytes of the ACPA-sIVIg, low-and high-dose IVIg and PBStreated CIA mice at day 38 by ELISPOT assay. The data are presented as AFCs activity per 10 5 cells mean 6 s.d. We assessed whether the reduced sera titres of ACPA and collagen-II antibodies upon treatment with ACPA-sIVIg were related to the number of antibody-forming B cells or to lower potential to secrete antibodies. Data presented in Table 1 show that ACPA-sIVIg treatment reduced the number of B cell-producing ACPA less than H-IVIg treatment (9 6 2 AFC in comparison to 38 6 3 AFC). L-IVIg treatment did not decrease the number of B cells AFC, 127 6 22 AFC when compared to 147 6 15 AFC of B cells purified from the PBS-treated groups of CIA mice (P > 0Á05). Similar results were achieved when B cell AFC activity was tested with collagen-II. ACPA sIVIg reduced anti-collagen-II AFC activity when compared to PBS treatment or exposure to L-IVIg (P < 0Á02). ACPA-sIVIGAFCs was 4Á2 times greater than H-IVIG, whereas no statistical significance was observed in the anti-collagen AFC activity in the ACPA-sIVIG-treated group of mice in comparison to the H-IVIG-treated group of mice. No statistical significance was noted in the anti-collagen-secreting cells between the AFC activity in the PBS-treated mice compared to AFC activity of the L-IVIg (P > 0Á05).
ACPA-sIVIg up-regulates expansion of T regulatory population in CIA mice
Recent reports have shown that IVIg treatment of CIA mice induced an increase in CD4 1 CD25 1 FoxP3 1 T regs , as in other autoimmune diseases [12] [13] [14] [15] . Therefore, we examined the ability of ACPA-sIVIg treatment to cause an increase in the CD4 1 CD25 1 FoxP3 1 T reg cell phenotype in CIA mice. The data presented in Fig. 4 show that ACPAsIVIg enhanced the percentage of T regs in CIA mice in the same manner as high-dose IVIg (P < 0Á001) when compared with CIA mice treated with low-dose IVIg or PBS. No significant difference was noted in the percentage of T regs in the splenocytes purified from high-dose IVIg and ACPA-sIVIg-treated mice (P > 0Á05).
ACPA-sIVIg effect on the cytokine inflammatory network
We assessed the effect of ACPA-sIVIg treatment on the profile of proinflammatory and anti-inflammatory cytokines secreted by splenocytes in vitro. ACPA-sIVIg significantly inhibited the secretion of the proinflammatory cytokines TNF-a and IL-1b, as demonstrated in Fig. 5 . The concentration of TNF-a in the culture fluid of splenocytes from ACPA-sIVIg-treated mice was 2Á3 times less than secretion by splenocytes derived from PBS or low-dose IVIg-treated mice. No significant difference in TNF-a secretion was observed between the effect of ACPA-sIVIg treatment and high-dose IVIg treatments (P > 0Á05). The concentrations of IL-1b in the culture fluid of splenocytes from ACPAsIVIg and high-dose IVIg treatments were 3Á6 and two times lower, respectively, in comparison to the IL-1b concentration in the culture fluid of the splenocytes from PBS or low-dose IVIg-treated CIA mice. ACPA-sIVIg enhanced secretion of anti-inflammatory cytokines by splenocytes in vitro. The concentrations of the anti-inflammatory cytokines IL-10 and TGF-b in the culture fluid of ACPA-sIVIg and high-dose IVIg-treated mice were increased significantly (P < 0Á001 and P < 0Á02, respectively) when compared with the IL-10 and TGF-b levels secreted by splenocytes originating from PBS and low-dose IVIg-treated mice.
Discussion
RA is a systemic disease that leads to painful joint destruction and disability [1] [2] [3] [4] [5] . The introduction of biological therapy, which targets specific elements of the immune Table 1 . Table 1 . Antibody-forming cell activity (AFC) upon treatment with anti-citrullinated peptides antibody-specific intravenous immunoglobulin (ACPA-sIVIg). system (e.g. anti-TNF, anti-IL-6 and kinase inhibitors), has revolutionized the treatment and outcomes of RA patients. Despite novel treatment strategies, not all patients respond well to therapy and a small number of RA patients remain partially or completely refractory to these and other conventional treatments. Biological treatments are costeffective. For several decades, RA was considered to be a cell-mediated autoimmune disease based on the successful induction of the disease in severe combined immunodeficient (SCID) mice by T cells derived from patients with RA, and vaccination with T cells was proposed as a treatment [24] [25] [26] . An additional revolutionary discovery was the diagnostic value of ACPA and their pathogenic role in RA [27] [28] [29] . ACPA-positive RA patients suffer from a more severe disease, with more aggressive erosions and extraarticular manifestations, compared to ACPA-negative RA patients [30, 31] . APCA were found to be pathogenic and directed to synovial citrullinated proteins and play a significant role in the pathogenesis of RA. Therefore, these antibodies may be targets for therapy [1] [2] [3] [4] [5] . Targeting the CD20 antigen by rituximab has been a successful therapeutic intervention in the treatment of RA [32] [33] [34] [35] . There is a basis to consider neutralization and immunomodulation of the pathogenic autoantibodies. Thus, IVIg for patients with RA has some advantages. IVIg has a wide range of immune modulatory activities with minimal side effects, and is no more expensive than most of the biological therapies. However, the mechanism by which IVIg immunomodulates the immune network in RA has not been completely clarified.
In our study, we have described one of the most important mechanisms for IVIg activity as an anti-idiotypic targeting and neutralizing agent. We show, for the first time, that the efficacy of anti-idiotypic anti-ACPA fraction of IVIg, named ACPA-sIVIg, inhibited ACPA activity in vitro. In addition, ACPA-sIVIg mitigated development of CIA in mice, which is a prototype model of RA and shares many clinical and histopathological similarities with RA patients [12, 24] . When injected into mice with CIA, ACPA-sIVIg led to a significant decline in the clinical joint inflammation score and was more effective than the entire IVIg preparation. Treatment with ACPA-sIVIg resulted in a more powerful decline in circulating anti-collagen and ACPA antibodies in comparison to the titres in mice treated with PBS or low-dose IVIg. Moreover, the decreased levels of autoantibodies correlated with less anti-collagen and ACPA antibody-forming cell (AFC) activity by the specific splenic B cells originating from CIA mice compared to AFC activity of B cells from the mice treated with PBS or low-dose IVIg. It was also evident that mice with CIA treated with ACPA-sIVIg demonstrated an increased percentage of T regs compared to their percentage in the mice treated with total IVIg preparation. Furthermore, a favourable effect of ACPA-sIVIg on IVIg at the same concentration was shown by the elevated levels of anti-inflammatory cytokines (IL-10, TGF-b) and a decrease in the secretion of proinflammatory levels of cytokines (TNF-a, IL-1b) by splenocytes in vitro. Similar outcomes were evident in this study following treatment of mice with CIA with the high-dose IVIg regimen. However, this was not observed with a low-dose IVIg regimen or with PBS treatment. These results suggest that ACPA-specific IVIg may have a beneficial on the whole IVIg preparation for patients with RA, as well for those with other autoimmune disorders. Our results are in agreement with our previous studies treating autoimmune experimental models with anti-idiotypes directed to the pathogenic autoantibodies that improved disease scores. Interestingly, antiidiotypic-sIVIg affected each autoimmune disease according to the animal presentation [17] [18] [19] [20] [21] . In lupus mice, lupussIVIg inhibited the immune complex deposition in the mesangium, as well as reducing the glomerulonephritis. In APS mice, in addition to neutralizing the pathogenic antibodies, APS-sIVIg enhanced the expression of MMP2/MMP9, which enabled successful embryo implantation. In small-vessel vasculitis, myeloperoxidase-sIVIg reduced neutrophils' oxidative burst, and in pemphigus mice pemphigus-sIVIg neutralized the anti-desmoglein-2/3 antibodies preventing the development of pemphigus. We suggest that clinical cases that did not respond to IVIg may react to the disease-specific IVIg. This concept does not revoke other mechanisms of IVIg activities via Fab portion, such as expansion of T regs , anti-cytokines, anti-chemokines, anti-receptors, adhesion molecules [14, [36] [37] [38] [39] or the role of sialylated Fc, which initiate an anti-inflammatory cascade through the lectin receptor-specific intercellular adhesion molecule-3 (ICAM-3) grabbing non-integrin-related-1 (SIGN-R1) or dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN), which leads to up-regulated surface expression of the inhibitory FcR, FcgammaRIIb, on inflammatory cells, thereby attenuating autoantibody-initiated inflammation [40, 41] . In summary, IVIg is an excellent preparation which, in the era of biological strategies, has additional wide-ranging capabilities, especially for those patients who do not respond to biological therapies.
